Novartis AG (NVS)
94.37
+1.80
(+1.94%)
USD |
NYSE |
Apr 19, 16:00
94.36
-0.02
(-0.02%)
After-Hours: 20:00
Novartis Revenue (TTM): 51.01B for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
| Date | Value |
|---|---|
| December 31, 2023 | 51.01B |
| September 30, 2023 | 50.20B |
| June 30, 2023 | 48.89B |
| March 31, 2023 | 48.04B |
| December 31, 2022 | 47.65B |
| September 30, 2022 | 41.30B |
| June 30, 2022 | 43.88B |
| March 31, 2022 | 44.09B |
| December 31, 2021 | 43.97B |
| September 30, 2021 | 52.38B |
| June 30, 2021 | 51.56B |
| March 31, 2021 | 49.88B |
| December 31, 2020 | 49.90B |
| September 30, 2020 | 49.58B |
| June 30, 2020 | 49.53B |
| March 31, 2020 | 49.93B |
| December 31, 2019 | 48.68B |
| September 30, 2019 | 47.86B |
| June 30, 2019 | 46.76B |
| March 31, 2019 | 46.39B |
| December 31, 2018 | 46.10B |
| September 30, 2018 | 40.64B |
| June 30, 2018 | 41.94B |
| March 31, 2018 | 42.78B |
| December 31, 2017 | 43.40B |
| Date | Value |
|---|---|
| September 30, 2017 | 49.58B |
| June 30, 2017 | 49.23B |
| March 31, 2017 | 49.41B |
| December 31, 2016 | 49.44B |
| September 30, 2016 | 49.63B |
| June 30, 2016 | 49.78B |
| March 31, 2016 | 50.00B |
| December 31, 2015 | 50.39B |
| September 30, 2015 | 50.94B |
| June 30, 2015 | 51.75B |
| March 31, 2015 | 52.80B |
| December 31, 2014 | 53.63B |
| September 30, 2014 | 53.91B |
| June 30, 2014 | 53.51B |
| March 31, 2014 | 52.84B |
| December 31, 2013 | 54.02B |
| September 30, 2013 | 49.87B |
| June 30, 2013 | 51.00B |
| March 31, 2013 | 52.26B |
| December 31, 2012 | 51.97B |
| September 30, 2012 | 57.49B |
| June 30, 2012 | 58.48B |
| March 31, 2012 | 59.07B |
| December 31, 2011 | 59.38B |
| September 30, 2011 | 58.84B |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
41.30B
Minimum
Sep 2022
52.38B
Maximum
Sep 2021
48.16B
Average
48.89B
Median
Jun 2023
Revenue (TTM) Benchmarks
| Sandoz Group AG | -- |
| Roche Holding AG | 67.72B |
| Amgen Inc | 28.19B |
| Incyte Corp | 3.696B |
| MorphoSys AG | 257.99M |